Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

Denali Therapeutics spinout raises $200M as neuro company resets

Tenvie is carrying over a collection of small molecule drugs that Denali had been developing but decided to discontinue work on.

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.

Tenvie Therapeutics Raises $200M in Funding

Tenvie Therapeutics, a San Francisco, CA-based biotechnology company committed to engineering small molecules for the treatment of neurological diseases, raised $200M in funding. The round was led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital, with participation from other investors. The company intends to use the funds to accelerate its growth and development efforts. Tenvie […] The post Tenvie Therapeutics Raises $200M in Funding…

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

A new startup has emerged with $200 million and access to multiple preclinical drug candidates from neuroscience drugmaker Denali Therapeutics. On Wednesday morning, South San Francisco-based Tenvie Therapeutics unveiled a large launch round from ARCH ...